HR Execs on the Move

AppianRx

www.appianrx.com

 
We are a healthcare solutions company that provides comprehensive and customized manufacturer patient support services and specialty pharmacy solutions. AppianRx leverages its unique and proprietary technology platform to deliver personalized services faster, smarter and more efficiently for patients, providers and manufacturer partners.
  • Number of Employees: 250-1000
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Ionetix

Ionetix Corporation is a pioneering radiopharmaceutical end to end solutions provider for cardiac PET. Cardiac PET with Ammonia N-13.

A Better Way

​A Better Way is a San Francisco Bay Area nonprofit that empowers children and families to develop the insights, life skills, and permanent relationships that promote their social, emotional, educational and economic well- being.

Glenmark Generics USA

Glenmark Generics USA is a Mahwah, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Amplity

You knew us as PHS Health Solutions, Touchpoint, Tardis Medical, and PDI, a family of leading pharmaceutical contract commercial organizations with a reputation as a trusted partner to our clients. And we`re still all that - but now we`re Amplity Health. Our vision is singular, so we wanted our corporate identity to match. We`ve consolidated our family of brands to offer customized and multichannel medical, remote engagement, and sales solutions, along with strategic consulting and organizational capability development into one company - and with one name—Amplity. Amplity is a new pure-play pharmaceutical commercialization partner that enjoys a 35-year track record. Our client-first passion elevates, accelerates, and amplifies commercial success from product to patient.

Oramed

Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in the United States and Israel, Oramed has developed a novel Protein Oral Delivery (POD™) technology. Oramed is seeking to transform the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which is being evaluated in two pivotal Phase 3 studies and has the potential to be the first commercial oral insulin capsule for the treatment of diabetes. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule (ORMD-0901).